HEERLEN, NETHERLANDS--(Marketwire - May 21, 2012) - Royal DSM (EURONEXT AMSTERDAM: DSM),
the global Life Sciences and Materials
Sciences company, announced today that its indirect wholly-owned
Biomedical Acquisition Corporation, has commenced its previously announced
tender offer for all outstanding shares of common stock of Kensey Nash
(NASDAQ: KNSY) at a price of $38.50 per share (the "Offer").
The tender offer is being made in connection with the Agreement and Plan of
Merger, dated as of 2 May 2012, by and among DSM, Biomedical Acquisition
Corporation and Kensey Nash, which DSM and Kensey Nash announced on 3 May
The Kensey Nash board of directors has unanimously determined that, among
things, the offer is fair to and in the best interests of Kensey Nash's
stockholders and unanimously recommends that Kensey Nash's stockholders
the offer and tender their shares.
The tender offer is scheduled to expire at 12:00 midnight (New York City
at the end of Monday, 18 June 2012, unless the offer is extended.
Complete terms and conditions of the tender offer are set forth in the
Purchase, Letter of Transmittal and other related materials that will be
by DSM and Biomedical Acquisition Corporation with the SEC on 21 May
addition, on 21 May 2012, Kensey Nash will file a
Statement on Schedule 14D-9 with the SEC relating to the offer. Copies
Offer to Purchase, Letter of Transmittal and other related
available free of charge from MacKenzie Partners, Inc., the information
for the tender offer, toll-free at (800) 322-2885. The depositary for the
offer is Citibank, N.A.
Kensey Nash is a medical device company primarily focused on
medicine utilizing its proprietary collagen and synthetic polymer
The company is recognized as a leader for innovative product
unique technology in the field of resorbable biomaterials. The company
extensive range of products, which are sold through strategic
multiple medical markets, including the cardiology, orthopedic, sports
spine, trauma, craniomaxillofacial and general surgery markets. For
information, visit http://www.kenseynash.com.
DSM - Bright Science. Brighter Living.™
Royal DSM is a global science-based company active in health, nutrition and
materials. By connecting its unique competences in Life Sciences and
Sciences DSM is driving economic prosperity, environmental progress and
advances to create sustainable value for all stakeholders. DSM delivers
innovative solutions that nourish, protect and improve performance in
markets such as food and dietary supplements, personal care, feed,
pharmaceuticals, medical devices, automotive, paints, electrical and
electronics, life protection, alternative energy and bio-based materials.
22,000 employees deliver annual net sales of around EUR 9 billion. The
listed on NYSE Euronext. More information can be found at www.dsm.com.
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: DSM N.V. via Thomson Reuters ONE